These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 16433803)

  • 1. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
    Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
    Br J Dermatol; 2006 Feb; 154(2):319-24. PubMed ID: 16433803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
    Br J Dermatol; 2006 Oct; 155(4):722-8. PubMed ID: 16965421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically.
    Iwai S; Sueki H; Watanabe H; Sasaki Y; Suzuki T; Iijima M
    J Dermatol; 2012 Sep; 39(9):781-6. PubMed ID: 22458564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology.
    Quaglino P; Caproni M; Antiga E; Del Bianco E; Osella-Abate S; Savoia P; Frezzolini A; Schena D; Marzano A; Volpi W; De Simone C; Parodi A; Fabbri P; Bernengo MG;
    Dermatology; 2007; 214(4):296-304. PubMed ID: 17460400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis.
    Hosaka H; Ohtoshi S; Nakada T; Iijima M
    J Dermatol; 2010 May; 37(5):407-12. PubMed ID: 20536645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
    Murata J; Abe R; Shimizu H
    J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.
    Chang YS; Huang FC; Tseng SH; Hsu CK; Ho CL; Sheu HM
    Cornea; 2007 Feb; 26(2):123-9. PubMed ID: 17251797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
    Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.
    Abe R; Shimizu T; Shibaki A; Nakamura H; Watanabe H; Shimizu H
    Am J Pathol; 2003 May; 162(5):1515-20. PubMed ID: 12707034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance and consequences of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in gynecology.
    Niemeijer IC; van Praag MC; van Gemund N
    Arch Gynecol Obstet; 2009 Nov; 280(5):851-4. PubMed ID: 19277691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Marzano AV; Frezzolini A; Caproni M; Parodi A; Fanoni D; Quaglino P; Girgenti V; La Placa M; Fabbri P; Caputo R; Berti E
    Int J Immunopathol Pharmacol; 2007; 20(3):557-66. PubMed ID: 17880768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal disease series. Number IV. Erythema multiforme.
    Farthing P; Bagan JV; Scully C
    Oral Dis; 2005 Sep; 11(5):261-7. PubMed ID: 16120111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.
    Chan HL; Stern RS; Arndt KA; Langlois J; Jick SS; Jick H; Walker AM
    Arch Dermatol; 1990 Jan; 126(1):43-7. PubMed ID: 2404462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
    Abe R
    J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial cell apoptosis in severe drug-induced bullous eruptions.
    Verneuil L; Ratajczak P; Allabert C; Leboeuf C; Comoz F; Janin A; Ameisen JC
    Br J Dermatol; 2009 Dec; 161(6):1371-5. PubMed ID: 19575754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Rzany B; Hering O; Mockenhaupt M; Schröder W; Goerttler E; Ring J; Schöpf E
    Br J Dermatol; 1996 Jul; 135(1):6-11. PubMed ID: 8776350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
    Watanabe R; Watanabe H; Sotozono C; Kokaze A; Iijima M
    Eur J Dermatol; 2011; 21(6):889-94. PubMed ID: 21873140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI
    Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Khalili B; Bahna SL
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Erythema multiforme vs. Stevens-Johnson syndrome and toxic epidermal necrolysis: an important diagnostic distinction].
    Rabelink NM; Brakman M; Maartense E; Bril H; Bakker-Wensveen CA; Bavinck JN
    Ned Tijdschr Geneeskd; 2003 Oct; 147(43):2089-94. PubMed ID: 14619195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.